Relaxin improves multiple markers of wound healing and ameliorates the disturbed healing pattern of genetically diabetic mice

Clinical Science

Volumn 125, Issue 12, 2013, Pages 575-585

  Bitto, Alessandra ^a   Irrera, Natasha ^a   Minutoli, Letteria ^a   Caló, Margherita ^b   Cascio, Patrizia Lo ^b   Caccia, Paolo ^c   Pizzino, Gabriele ^a   Pallio, Giovanni ^a   Micali, Antonio ^b   Vaccaro, Mario ^b   Saitta, Antonino ^b   Squadrito, Francesco ^a   Altavilla, Domenica ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c IBSA Institut Biochimique SA   (Switzerland)

Author keywords

Angiogenesis; Diabetes; Matrix metalloproteinase (MMP); Relaxin; Vascular endothelial growth factor (VEGF); Wound healing

Indexed keywords

CD34 ANTIGEN; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUCOSE; MESSENGER RNA; RELAXIN; STROMAL CELL DERIVED FACTOR 1ALPHA; STROMELYSIN 3; VASCULAR ENDOTHELIAL CADHERIN; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EXPERIMENTAL DIABETES MELLITUS; FEMALE; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; SKIN INCISION; SKIN INJURY; TENSILE STRENGTH; WOUND CLOSURE; WOUND HEALING IMPAIRMENT;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD34; BLOOD GLUCOSE; CADHERINS; CHEMOKINE CXCL12; DIABETES COMPLICATIONS; FEMALE; MATRIX METALLOPROTEINASE 11; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PHYSIOLOGIC; NITRIC OXIDE; RELAXIN; SWINE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; WOUND HEALING;

EID: 84883759083     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20130105     Document Type: Article

References (40)

1. Falanga, V. (2005) Wound healing and its impairment in the diabetic foot. Lancet 366, 1736-1743
2. Singh, N., Armstrong, D. G. and Lipsky, B. A. (2005) Preventing foot ulcers in patients with diabetes. JAMA, J. Am. Med. Assoc. 293, 217-228
3. Reiber, G. E. and Raugi, G. J. (2005) Preventing foot ulcers and amputations in diabetes. Lancet 366, 1676-1677
4. Ferrara, N., Gerber, H. P. and LeCouter, J. (2003) The biology of VEGF and its receptors. Nat. Med. 9, 669-676
5. Tammela, T., Enholm, B., Alitalo, K. and Paavonen, K. (2005) The biology of vascular endothelial growth factors. Cardiovasc. Res. 65, 550-563
6. Goodson, W. H. and Hunt, T. K. (1977) Studies of wound healing in experimental diabetes. J. Surg. Res. 22, 221-227
7. Bohlen, H. G. and Niggl, B. A. (1979) Adult microvascular disturbances as a result of juvenile-onset diabetes in db/db mice. Blood Vessels 16, 269-276
8. Altavilla, D., Saitta, A., Cucinotta, D., Galeano, M., Deodato, B., Colonna, M., Torre, V., Russo, G., Sardella, A., Urna, G. et al. (2001) Inhibition of lipid peroxidation restores impaired vascular endothelial growth factor expression and stimulates wound healing and angiogenesis in the genetically diabetic mouse. Diabetes 50, 667-674
9. Galeano, M., Deodato, B., Altavilla, D., Cucinotta, D., Arsic, N., Marini, H., Torre, V., Giacca, M. and Squadrito, F. (2003) Adeno-associated viral vector-mediated human vascular endothelial growth factor gene transfer stimulates angiogenesis and wound healing in the genetically diabetic mouse. Diabetologia 46, 546-555
10. Peichev, M., Naiyer, A. J., Pereira, D., Zhu, Z., Lane, W. J., Williams, M., Oz, M. C., Hicklin, D. J., Witte, L., Moore, M. A. et al. (2000) Expression of VEGFR-2 and AC133 by circulating human CD34+ cells identifies a population of functional endothelial precursors. Blood 95, 952-958
11. Asahara, T., Masuda, H. and Takahashi, T. (1999) Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ. Res. 85, 221-228
12. Urbich, C. and Dimmeler, S. (2004) Endothelial progenitor cells functional characterization. Trends Cardiovasc. Med. 14, 318-322
13. Wetzler, C., Kampfer, H., Stallmeyer, B., Pfeilschifter, J. and Frank, S. (2000) Large and sustained induction of chemokines during impaired wound healing in the genetically diabetic mouse: prolonged persistence of neutrophils and macrophages during the late phase of repair. J. Invest. Dermatol. 115, 245-253
14. Brem, H. and Tomic-Canic, M. (2007) Cellular and molecular basis of wound healing in diabetes. J. Clin. Invest. 117, 1219-1222
15. Kong, R. C., Shilling, P. J., Lobb, D. K., Gooley, P. R. and Bathgate, R. A. (2010) Membrane receptors: structure and function of the relaxin family peptide receptors. Mol. Cell. Endocrinol. 320, 1-15
16. Unemori, E. N., Lewis, M., Constant, J., Arnold, G., Grove, B. H., Normand, J., Deshpande, U., Salles, A., Pickford, L. B., Erikson, M. E. et al. (2000) Relaxin induces vascular endothelial growth factor expression and angiogenesis selectively at wound sites. Wound Repair Regen. 8, 361-370
17. Mookerjee, I., Unemori, E. N., Du, X. J., Tregear, G. W. and Samuel, C. S. (2005) Relaxin modulates fibroblast function, collagen production, and matrix metalloproteinase-2 expression by cardiac fibroblasts. Ann. N.Y. Acad. Sci. 1041, 190-193
18. Beiler, J. M., McBurney, E. A., Patchman, E. A., Pizzaia, L. M. and Martin, G. J. (1960) Effects of relaxin on wound healing. Arch. Int. Pharmacodyn. Ther. 123, 291-294
19. Stewart, D. R. (2009) Scar prevention and cosmetically enhanced wound healing usingrelaxin. Ann. N.Y. Acad. Sci. 1160, 336-341
20. Altavilla, D., Squadrito, F., Polito, F., Irrera, N., Caló, M., Lo Cascio, P., Galeano, M., La Cava, L., Minutoli, L., Marini, H. et al. (2011) Activation of adenosine A2A receptors restores the altered cell-cycle machinery during impaired wound healing in genetically diabetic mice. Surgery 149, 253-261
21. Galeano, M., Bitto, A., Altavilla, D., Minutoli, L., Polito, F., Caló, M., Lo Cascio, P., Stagno d'Alcontres, F. and Squadrito, F. (2008) Polydeoxyribonucleotide stimulates angiogenesis and wound healing in the genetically diabetic mouse. Wound Repair. Regen. 16, 208-217
22. Galeano, M., Altavilla, D., Bitto, A., Minutoli, L., Caló, M., Lo Cascio, P., Polito, F., Giugliano, G., Squadrito, G., Mioni, C. et al. (2006) Recombinant human erythropoietin improves angiogenesis and wound healing in experimental burn wounds. Crit. Care Med. 34, 1139-1146
23. Galeano, M., Polito, F., Bitto, A., Irrera, N., Campo, G. M., Avenoso, A., Caló, M., Lo Cascio, P., Minutoli, L., Barone, M. et al. (2011) Systemic administration of high-molecular weight hyaluronan stimulates wound healing in genetically diabetic mice. Biochim. Biophys. Acta 18127, 752-759
24. Galeano, M., Torre, V., Deodato, B., Campo, G. M., Colonna, M., Sturiale, A., Squadrito, F., Cavallari, V., Cucinotta, D., Buemi, M. et al. (2001) Raxofelast, a hydrophilic vitamin E-like antioxidant, stimulates wound healing in genetically diabetic mice. Surgery 129, 467-477
25. Bani, D. (2008) Relaxin as a natural agent for vascular health. Vasc. Health Risk Manag. 4, 515-524
26. Unemori, E. N., Erikson, M. E., Rocco, S. E., Sutherland, K. M., Parsell, D. A., Mak, J. and Grove, B. H. (1999) Relaxin stimulates expression of vascular endothelial growth factor in normal human endometrial cells in vitro and is associated with menometrorrhagia in women. Hum. Reprod. 14, 800-806
27. Piccinni, M. P., Bani, D., Beloni, L., Manuelli, C., Mavilia, C., Vocioni, F., Bigazzi, M., Sacchi, T. B., Romagnani, S. and Maggi, E. (1999) Relaxin favors the development of activated human T cells into Th1-like effectors. Eur. J. Immunol. 29, 2241-2247
28. Masini, E., Nistri, S., Vannacci, A., Bani Sacchi, T., Novelli, A. and Bani, D. (2004) Relaxin inhibits the activation of human neutrophils: involvement of the nitric oxide pathway. Endocrinology 145, 1106-1112
29. Vestweber, D., Winderlich, M., Cagna, G. and Nottebaum, A. F. (2009) Cell adhesion dynamics at endothelial junctions: VE-cadherin as a major player. Trends Cell Biol. 19, 8-15
30. Boswell, C. A., Ferl, G. Z., Mundo, E. E., Bumbaca, D., Schweiger, M. G., Theil, F. P., Fielder, P. J. and Khawli, L. A. (2011) Effects of anti-VEGF on predicted antibody biodistribution: roles of vascular volume, interstitial volume, and blood flow. PLoS ONE 6, e17874
31. Kioi, M., Vogel, H., Schultz, G., Hoffman, R. M., Harsh, G. R. and Brown, J. M. (2010) Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J. Clin. Invest. 120, 694-705
32. Hunt, T. K., Hopf, H. and Hussain, Z. (2000) Physiology of wound healing. Adv. Skin Wound Care 13, 6-11
33. Negishi, S., Li, Y., Usas, A., Fu, F. H. and Huard, J. (2005) The effect of relaxin treatment on skeletal muscle injuries. Am. J. Sports Med. 33, 1816-1824
34. Williams, E. J., Benyon, R. C., Trim, N., Hadwin, R., Grove, B. H., Arthur, M. J., Unemori, E. N. and Iredale, J. P. (2001) Relaxin inhibits effective collagen deposition by cultured hepatic stellate cells and decreases rat liver fibrosis in vivo. Gut 49, 577-583
35. Garber, S. L., Mirochnik, Y., Brecklin, C. S., Unemori, E. N., Singh, A. K., Slobodskoy, L., Grove, B. H., Arruda, J. A. and Dunea, G. (2001) Relaxin decreases renal interstitial fibrosis and slows progression of renal disease. Kidney Int. 59, 876-882
36. Unemori, E. N. and Amento, E. P. (1990) Relaxin modulates synthesis and secretion of procollagenase and collagen by human dermal fibroblasts. J. Biol. Chem. 265, 10681-10685
37. Samuel, C. S. (2005) Relaxin: antifibrotic properties and effects in models of disease. Clin. Med. Res. 3, 241-249
38. Teerlink, J. R., Metra, M., Felker, G. M., Ponikowski, P., Voors, A. A., Weatherley, B. D., Marmor, A., Katz, A., Grzybowski, J., Unemori, E. et al. (2009) Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet 373, 1429-1439
39. Boussageon, R., Bejan-Angoulvant, T., Saadatian-Elahi, M., Lafont, S., Bergeonneau, C., Kassaïi, B., Erpeldinger, S., Wright, J. M., Gueyffier, F. and Cornu, C. (2011) Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ. 343, d4169
40. Voors, A. A. and van der Horst, I. C. (2011) Diabetes: a driver for heart failure. Heart 97, 774-780